{"DataElement":{"publicId":"14675033","version":"1","preferredName":"Patient Neuroblastoma Disease or Disorder Assignment International Neuroblastoma Risk Group Neoplasm Stage","preferredDefinition":"A description of the patient's disease group based on the International Neuroblastoma Risk Group stage.","longName":"PT_INRG_STG","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5774022","version":"1","preferredName":"Patient Neuroblastoma Disease or Disorder Assignment","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._An allotting or an appointment to a particular person or use, or for a particular time or object.","longName":"2233604v1.0:5774020v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5774020","version":"1","preferredName":"Neuroblastoma Disease or Disorder Assignment","preferredDefinition":"A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:An allotting or an appointment to a particular person or use, or for a particular time or object.","longName":"C3270:C2991:C25426","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D132939-27F5-3938-E053-F662850A352F","latestVersionIndicator":"Yes","beginDate":"2017-04-13","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-13","modifiedBy":"ONEDATA","dateModified":"2017-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D132939-2806-3938-E053-F662850A352F","latestVersionIndicator":"Yes","beginDate":"2017-04-13","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-13","modifiedBy":"ONEDATA","dateModified":"2017-04-13","changeDescription":"ANBL1531-PDC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"14675028","version":"1","preferredName":"International Neuroblastoma Risk Group Neoplasm Stage","preferredDefinition":"An international consortium of cooperative groups with expertise in neuroblastoma that established a consensus pre-treatment International Neuroblastoma Risk Group (INRG) classification system._The extent of a cancer in the body.","longName":"14675028v1.00","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"300","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification","valueDescription":null,"ValueMeaning":{"publicId":"14675029","version":"1","preferredName":"Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification","longName":"14675029v1.00","preferredDefinition":"Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E97C32A-B44E-5DA8-E063-731AD00ABF05","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E97C32A-B450-5DA8-E063-731AD00ABF05","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to Stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)","valueDescription":null,"ValueMeaning":{"publicId":"14675030","version":"1","preferredName":"Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to Stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)","longName":"14675030v1.00","preferredDefinition":"Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to Stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E97C32A-B44F-5DA8-E063-731AD00ABF05","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E97C32A-B451-5DA8-E063-731AD00ABF05","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Age ≥ 547 days and INRG Stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)","valueDescription":null,"ValueMeaning":{"publicId":"14675031","version":"1","preferredName":"Age ≥ 547 days and INRG Stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)","longName":"14675031v1.00","preferredDefinition":"Age ≥ 547 days and INRG Stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E97CCE0-47CF-5F98-E063-731AD00A1CB9","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E97CCE0-47D1-5F98-E063-731AD00A1CB9","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to Stage M without systemic chemotherapy","valueDescription":null,"ValueMeaning":{"publicId":"14675032","version":"1","preferredName":"Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to Stage M without systemic chemotherapy","longName":"14675032v1.00","preferredDefinition":"Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to Stage M without systemic chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E97CCE0-47D0-5F98-E063-731AD00A1CB9","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E97CCE0-47D2-5F98-E063-731AD00A1CB9","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"14675034","version":"1","preferredName":"International Neuroblastoma Risk Group Neoplasm Stage","preferredDefinition":"An international consortium of cooperative groups with expertise in neuroblastoma that established a consensus pre-treatment International Neuroblastoma Risk Group (INRG) classification system._The extent of a cancer in the body.","longName":"14675034v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Neuroblastoma Risk Group","conceptCode":"C192760","definition":"An international consortium of cooperative groups with expertise in neuroblastoma that established a consensus pre-treatment International Neuroblastoma Risk Group (INRG) classification system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E982EB9-55C6-723E-E063-731AD00A1933","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0E97B395-DA81-5B2B-E063-731AD00A7424","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"PAT_DIS_GROUP","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the patient's disease group based on the International Neuroblastoma Risk Group stage?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"What is patient's disease group?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0E97E774-6BAE-6723-E063-731AD00AE3E1","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":"2023.1.10 Created per ticket request CADSR0003241. ak","unresolvedIssues":null,"deletedIndicator":"No"}}